ReviewCancer science2018
Breast cancer: The translation of big genomic data to cancer precision medicine.
Review in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Capturing artificial intelligence applications' value proposition in healthcare - a qualitative research study.BMC health services research · 2024Pooled it
- Identification of a migracytosis and angiogenesis-associated lncRNAs signature in immunotherapy in breast cancer.Journal of applied genetics · 2026Article
- Leveraging a chromosomal instability-based signature to predict the prognosis and immune landscape of breast cancer.Genes & diseases · 2026Article
- Meta-Analysis and Experimental Studies Reveal Mitotic Network Activity Index (MNAI) as Breast Cancer Metastasis and Treatment Biomarker.Life (Basel, Switzerland) · 2025Article
- Revolutionizing Breast Cancer Therapeutics: Intersecting Frontiers of Precision Medicine, Nanotechnology, and Drug Delivery Innovations.Current treatment options in oncology · 2025Review
- Hypoxia-driven angiogenesis in breast cancer mechanisms and therapeutic targets: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Oxygen deprivation in breast cancer: mechanisms, pathways, and implications.Annals of medicine and surgery (2012) · 2025Review
- Review
- Big data for neuroscience in the context of predictive, preventive, and personalized medicine.The EPMA journal · 2025Review
- A Circadian Rhythm-related Signature to Predict Prognosis, Immune Infiltration, and Drug Response in Breast Cancer.Current medicinal chemistry · 2025Article
- Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis.Breast cancer research : BCR · 2024Review
- Exploring the Synergistic Mechanism of AP2A2 Transcription Factor Inhibition via Molecular Modeling and Simulations as a Novel Computational Approach for Combating Breast Cancer: In Silico Interpretations.Molecular biotechnology · 2024Article
- Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine.Journal of personalized medicine · 2024Review
- Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice.Medicina (Kaunas, Lithuania) · 2024Review
- Challenges and Opportunities for Data Science in Women's Health.Annual review of biomedical data science · 2023Review
- MRI-based breast cancer radiogenomics using RNA profiling: association with subtypes in a single-center prospective study.Breast cancer research : BCR · 2023Article
- Deep Learning Techniques with Genomic Data in Cancer Prognosis: A Comprehensive Review of the 2021-2023 Literature.Biology · 2023Article
- miRNA-874-3p inhibits the migration, invasion and proliferation of breast cancer cells by targeting VDAC1.Aging · 2023Article
- A novel risk score model based on gamma-aminobutyric acid signature predicts the survival prognosis of patients with breast cancer.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a complex genetic disease that develops from the accumulation of genomic alterations in which germline variations predispose individuals to cancer and somatic alterations initiate and trigger the progression of cancer. For the past 2 decades, genomic research has advanced remarkably, evolving from single-gene to whole-genome screening by using genome-wide association study and next-generation sequencing that contributes to big genomic data. International collaborative efforts have contributed to curating these data to identify clinically significant alterations that could be used in clinical settings. Focusing on breast cancer, the present review summarizes the identification of genomic alterations with high-throughput screening as well as the use of genomic information in clinical trials that match cancer patients to therapies, which further leads to cancer precision medicine. Furthermore, cancer screening and monitoring were enhanced greatly by the use of liquid biopsies. With the growing data complexity and size, there is much anticipation in exploiting deep machine learning and artificial intelligence to curate integrative "-omics" data to refine the current medical practice to be applied in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.